News Summary: J&J 3Q net income down, sales up

Published



PROFIT DROP: Third-quarter net income dropped 7 percent for health care giant Johnson & Johnson, to $2.97 billion, or $1.05 per share, but after adjusting for one-time charges, it beat Wall Street expectations.

SALES CLIMB: Revenue rose 6.5 percent to $17.05 billion. Revenue from prescription medicines and medical devices increased. Consumer health sales declined due to recalls continuing to keep some nonprescription medicines out of stores.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.